Psyence Biomedical Ltd.
PBM · NASDAQ
9/30/2025 | 9/30/2024 | 12/31/2023 | 9/30/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.00 | -0.32 | -15.34 |
| FCF Yield | 0.00% | 0.00% | -0.00% | -0.00% |
| EV / EBITDA | 3.28 | 103.26 | -104,537.85 | -69,891.49 |
| Quality | ||||
| ROIC | -12.69% | -92.88% | 120,283.04% | 29.49% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.03 | 0.39 | 4.00 | 22.47 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 0.00% | 0.00% | 99.74% | -0.01% |
| Safety | ||||
| Net Debt / EBITDA | 9.61 | 3.89 | -0.02 | -2.73 |
| Interest Coverage | -547.15 | -311.47 | 0.00 | -20.21 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -71,363.36 | 0.00 | 0.00 |